[go: up one dir, main page]

AU2001295263A1 - Method of identifying abnormal immune reactions - Google Patents

Method of identifying abnormal immune reactions

Info

Publication number
AU2001295263A1
AU2001295263A1 AU2001295263A AU9526301A AU2001295263A1 AU 2001295263 A1 AU2001295263 A1 AU 2001295263A1 AU 2001295263 A AU2001295263 A AU 2001295263A AU 9526301 A AU9526301 A AU 9526301A AU 2001295263 A1 AU2001295263 A1 AU 2001295263A1
Authority
AU
Australia
Prior art keywords
leukocytes
subject
expression
control
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295263A
Inventor
Patrick Holt
Claudia Macaubas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telethon Kids Institute TVW
Original Assignee
Telethon Kids Institute TVW
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telethon Kids Institute TVW filed Critical Telethon Kids Institute TVW
Priority to AU2001295263A priority Critical patent/AU2001295263A1/en
Publication of AU2001295263A1 publication Critical patent/AU2001295263A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A method for diagnosis of immunologically-mediated conditions such as allergic conditions, autoimmune diseases and immunological deficiency, and of assessing immunological reactivity associated with conditions such as viral infections, cancer, AIDS, tissue transplantation and the like. the method comprises: Taking a sample from a subject suspected to be manifesting an abnormal immunological reaction; isolating leukocytes from subject and a control; measuring the level of expression of a transcription factor in unstimulated leukocytes; stimulating the leukocytes by exposure to a stimulus; measuring the level of expression of a transcription factor in stimulated leukocytes; comparing results of stimulated and unstimulated leukocytes from subject and control; a significant difference in expression between the subject and control is indicative of an abnormal immunological reaction.
AU2001295263A 2000-10-13 2001-10-11 Method of identifying abnormal immune reactions Abandoned AU2001295263A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001295263A AU2001295263A1 (en) 2000-10-13 2001-10-11 Method of identifying abnormal immune reactions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR0779A AUPR077900A0 (en) 2000-10-13 2000-10-13 Immunodiagnosis
AUPR0779 2000-10-13
AU2001295263A AU2001295263A1 (en) 2000-10-13 2001-10-11 Method of identifying abnormal immune reactions
PCT/AU2001/001282 WO2002031185A1 (en) 2000-10-13 2001-10-11 Method of identifying abnormal immune reactions

Publications (1)

Publication Number Publication Date
AU2001295263A1 true AU2001295263A1 (en) 2002-04-22

Family

ID=3824837

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPR0779A Abandoned AUPR077900A0 (en) 2000-10-13 2000-10-13 Immunodiagnosis
AU2001295263A Abandoned AU2001295263A1 (en) 2000-10-13 2001-10-11 Method of identifying abnormal immune reactions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AUPR0779A Abandoned AUPR077900A0 (en) 2000-10-13 2000-10-13 Immunodiagnosis

Country Status (6)

Country Link
US (1) US20040063149A1 (en)
EP (1) EP1332225B1 (en)
AT (1) ATE413468T1 (en)
AU (2) AUPR077900A0 (en)
DE (1) DE60136480D1 (en)
WO (1) WO2002031185A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026807A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents for treatment or prevention of an allergic disorder
WO2006026808A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Method of diagnosing and/or predicting the development of an allergic disorder
US20100021424A1 (en) * 2006-06-02 2010-01-28 Vincent Brichard Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy
WO2008091814A2 (en) * 2007-01-22 2008-07-31 Wyeth Assessment of asthma and allergen-dependent gene expression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829009A (en) * 1986-02-21 1989-05-09 The Regents Of The University Of California Noise controlled immunoassays
US6190857B1 (en) * 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
AU1401999A (en) * 1997-12-12 1999-07-05 Alpha-Beta Technology, Inc. Activation of transcription factor complex by beta(1-3) glucan
US6287805B1 (en) * 1998-03-20 2001-09-11 Millennium Pharmaceuticals, Inc. Nucleic acid molecules of the protein-coupled heptahelical receptor superfamily and uses therefor
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor

Also Published As

Publication number Publication date
ATE413468T1 (en) 2008-11-15
DE60136480D1 (en) 2008-12-18
AUPR077900A0 (en) 2000-11-09
EP1332225A1 (en) 2003-08-06
WO2002031185A8 (en) 2002-06-20
EP1332225B1 (en) 2008-11-05
US20040063149A1 (en) 2004-04-01
WO2002031185A1 (en) 2002-04-18
EP1332225A4 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
Ujiie Regulatory T cells in autoimmune skin diseases
NO20056236L (en) Treatment with anti-VEGF antibodies
AU2003263834A8 (en) Mutations in nod2 are associated with fibrostenosing disease in patients with crohn's disease
Lim et al. Semi‐mature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen‐induced arthritis mice
IL162722A (en) In vitro method of identifying abnormal cervical cell changes in humans and kit therefor
Díaz‐Zúñiga et al. Increased levels of the T‐helper 22‐associated cytokine (interleukin‐22) and transcription factor (aryl hydrocarbon receptor) in patients with periodontitis are associated with osteoclast resorptive activity and severity of the disease
Bending et al. Epigenetic changes at Il12rb2 and Tbx21 in relation to plasticity behavior of Th17 cells
EP1563300A4 (en) METHOD FOR DIAGNOSING CELIAC DISEASE
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
EP1797431A4 (en) Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
Long et al. Upregulated IL‐17A secretion and CCR6 co‐expression in Treg subsets are related to the imbalance of Treg/Th17 cells in active UC patients
AU2002315411A1 (en) Detection and treatment of prostate cancer
Zhang The epigenetics of autoimmunity
Jiao et al. Normal mesenchymal stem cells can improve the abnormal function of T cells in psoriasis via upregulating transforming growth factor‐β receptor
AU2001295263A1 (en) Method of identifying abnormal immune reactions
Wang et al. Interleukin‐17A potentiates interleukin‐13‒induced eotaxin‐3 production by human nasal epithelial cells from patients with allergic rhinitis
DE60039863D1 (en) USE OF CYTOKINES AND MITOGENS FOR THE INHIBITION OF PATHOLOGICAL IMMUNE RESPONSES
GB9610281D0 (en) Diagnostic method and apparatus
WO2001029070A3 (en) Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
AU2002306568A1 (en) Forms of prostate specific antigens and methods for their detection
ATE532065T1 (en) ANTIGEN TARGETS OF AUTOIMMUNE SENSORNETINE HEARING LOSS (AISNHL) AND DEVELOPMENT OF TESTS FOR THE DIAGNOSIS AND TREATMENT OF AISNHL
Lim et al. The Role of T‐Helper 17 Cells and Regulatory T Cells in Acute Diffuse and Total Alopecia: The Increased Function of Regulatory T Cells May Explain the Favorable Prognosis
GB0227274D0 (en) Probes
EP1722225A4 (en) A method for diagnosing immunity recurrent spontaneous abortion and method for treating and monitoring
Gallego-Valle et al. Ectopic FOXP3 Expression in Combination with TGF-β1 and IL-2 Stimulation Generates Limited Suppressive Function in Human Primary Activated Thymocytes Ex Vivo. Biomedicines 2021, 9, 461